About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Therapeutic Advances in Infectious Disease
›
top-articles
Therapeutic Advances in Infectious Disease
3.2
(top 10%)
impact factor
306
(top 50%)
papers
3.7K
(top 20%)
citations
26
(top 20%)
h
-index
3.5
(top 10%)
impact factor
403
all documents
4.3K
doc citations
54
(top 20%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Carbapenem resistance: overview of the problem and future perspectives
Therapeutic Advances in Infectious Disease
2016
397
2
The role of nanotechnology in the treatment of viral infections
Therapeutic Advances in Infectious Disease
2017
233
3
Recent advances in the understanding of antibiotic resistance in
Clostridium difficile
infection
Therapeutic Advances in Infectious Disease
2016
212
4
Extrahepatic manifestations of chronic hepatitis C virus infection
Therapeutic Advances in Infectious Disease
2016
176
5
Blastocystis
, an unrecognized parasite: an overview of pathogenesis and diagnosis
Therapeutic Advances in Infectious Disease
2013
154
6
The global problem of childhood diarrhoeal diseases: emerging strategies in prevention and management
Therapeutic Advances in Infectious Disease
2018
132
7
The role of the healthcare environment in the spread of multidrug-resistant organisms: update on current best practices for containment
Therapeutic Advances in Infectious Disease
2014
103
8
Recent developments and future prospects in the treatment of visceral leishmaniasis
Therapeutic Advances in Infectious Disease
2016
99
9
Extrapulmonary tuberculosis: are statistical reports accurate?
Therapeutic Advances in Infectious Disease
2014
95
10
COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review
Therapeutic Advances in Infectious Disease
2021
85
11
The emerging SARS-CoV-2 variants of concern
Therapeutic Advances in Infectious Disease
2021
82
12
Azithromycin, cardiovascular risks, QTc interval prolongation,
torsade de pointes
, and regulatory issues: A narrative review based on the study of case reports
Therapeutic Advances in Infectious Disease
2013
75
13
Management of community-acquired pneumonia in older adults
Therapeutic Advances in Infectious Disease
2014
68
14
Hepatitis E: an underestimated emerging threat
Therapeutic Advances in Infectious Disease
2019
66
15
Respiratory syncytial virus: diagnosis, prevention and management
Therapeutic Advances in Infectious Disease
2019
65
16
The host immune response to
Clostridium difficile
infection
Therapeutic Advances in Infectious Disease
2013
53
17
Clinical management of infections caused by multidrug-resistant
Enterobacteriaceae
Therapeutic Advances in Infectious Disease
2013
50
18
Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure
Therapeutic Advances in Infectious Disease
2017
50
19
Antimicrobial effects of lysophosphatidylcholine on methicillin-resistant
Staphylococcus aureus
Therapeutic Advances in Infectious Disease
2017
50
20
Best practice in the prevention and management of paediatric respiratory syncytial virus infection
Therapeutic Advances in Infectious Disease
2016
49
21
Invasive fungal infections in transplant recipients
Therapeutic Advances in Infectious Disease
2013
45
22
Climate change and antibiotic resistance: a deadly combination
Therapeutic Advances in Infectious Disease
2021
40
23
COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs
Therapeutic Advances in Infectious Disease
2021
36
24
COVID-19 vaccine hesitancy among staff and students in a Nigerian tertiary educational institution
Therapeutic Advances in Infectious Disease
2021
36
25
Viral infections and the development of asthma in children
Therapeutic Advances in Infectious Disease
2013
35
26
COVID-19 vaccine acceptance among high-risk populations in Uganda
Therapeutic Advances in Infectious Disease
2021
33
27
Risk factors and outcomes for multidrug-resistant Gram-negative bacilli bacteremia
Therapeutic Advances in Infectious Disease
2018
32
28
Management of febrile neutropenia in the era of bacterial resistance
Therapeutic Advances in Infectious Disease
2013
30
29
The implications of whole-genome sequencing in the control of tuberculosis
Therapeutic Advances in Infectious Disease
2016
28
30
Infectious complications of CAR T-cell therapy: a clinical update
Therapeutic Advances in Infectious Disease
2021
28
31
Urogenital tuberculosis: definition and classification
Therapeutic Advances in Infectious Disease
2014
26
32
Advances in hepatitis B therapeutics
Therapeutic Advances in Infectious Disease
2020
26
33
Monkeypox – a description of the clinical progression of skin lesions: a case report from Colorado, USA
Therapeutic Advances in Infectious Disease
2022
26
34
How to manage KPC infections
Therapeutic Advances in Infectious Disease
2020
25
35
Optimal treatment of HIV-associated neurocognitive disorders: myths and reality. A critical review
Therapeutic Advances in Infectious Disease
2019
24
36
Community-acquired pneumonia: identification and evaluation of nonresponders
Therapeutic Advances in Infectious Disease
2013
23
37
Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant
Staphylococcus aureus
bacteremia after monotherapy failure
Therapeutic Advances in Infectious Disease
2019
23
38
Symptom cluster analysis of long COVID-19 in patients discharged from the Temporary COVID-19 Hospital in Mexico City
Therapeutic Advances in Infectious Disease
2022
23
39
Current tools available for the diagnosis of drug-resistant tuberculosis
Therapeutic Advances in Infectious Disease
2016
22
40
Oral mucositis caused by
Candida glabrata
biofilms: failure of the concomitant use of fluconazole and ascorbic acid
Therapeutic Advances in Infectious Disease
2017
22
41
Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster
Therapeutic Advances in Infectious Disease
2020
22
42
Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments
Therapeutic Advances in Infectious Disease
2014
21
43
Visceral scalloping on abdominal computed tomography due to abdominal tuberculosis
Therapeutic Advances in Infectious Disease
2017
21
44
Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiograms
Therapeutic Advances in Infectious Disease
2021
21
45
Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance
Therapeutic Advances in Infectious Disease
2020
20
46
Risk of infection associated with targeted therapies for solid organ and hematological malignancies
Therapeutic Advances in Infectious Disease
2021
20
47
SARS-CoV-2 RNA in the Cerebrospinal Fluid of a Patient with Long COVID
Therapeutic Advances in Infectious Disease
2021
20
48
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens
Therapeutic Advances in Infectious Disease
2017
19
49
Utility of tissue Xpert-Mtb/Rif for the diagnosis of intestinal tuberculosis in patients with ileocolonic ulcers
Therapeutic Advances in Infectious Disease
2019
18
50
Antiretroviral adherence for adolescents growing up with HIV: understanding real life, drug delivery and forgiveness
Therapeutic Advances in Infectious Disease
2020
18
site/software ©
exaly
; All materials licenced under
CC by-SA
.